Please login to the form below

Not currently logged in
Email:
Password:

Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Following after in MS is ofatumumab, a potential rival to Roche’s fast-growing CD20-targeting drug Ocrevus (ocrelizumab) that is already approved to treat blood cancers under the Arzerra (brand

Latest news

  • Roche’s new flu pill Xofluza approved in US Roche’s new flu pill Xofluza approved in US

    This week saw the company unveil strong Q3 results, which managed to overcome the biosimilar onslaught, thanks to growth in new products such as multiple sclerosis drug Ocrevus.

  • Spinraza lifts Biogen ahead of Alzheimer’s data Spinraza lifts Biogen ahead of Alzheimer’s data

    from newer drugs such as Roche’s Ocrevus (ocrelizumab). ... MS drug sales came in at $2.3bn, with Tecfidera static at $1.09bn, and while Biogen gets a royalty stream from Ocrevus sales, that did little to counteract the impact

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    Sales of Roche’s new multiple sclerosis therapy Ocrevus more than tripled in the first nine months of 2018, helping to compensate for the loss of patent protection on its older ... Ocrevus (ocrelizumab) only made its debut in the US last year, but has

  • Novartis files for approval of MS drug in EU, US Novartis files for approval of MS drug in EU, US

    That includes Roche‘s new therapy Ocrevus (ocrelizumab), a humanised monoclonal antibody designed to selectively target CD20-positive B cells, which has been approved in relapsing forms of MS and primary ... Ocrevus’ indications does however cover

  • Dismay as NICE rejects Roche’s MS drug Ocrevus Dismay as NICE rejects Roche’s MS drug Ocrevus

    Treatment deemed too costly to treat primary progressive MS. The NHS will not fund treatment with Roche’s recently-approved multiple sclerosis drug Ocrevus, even though it is the only treatment ... 600mg infusion every six months – but is being

More from news
Approximately 14 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics